Company Quick10K Filing
Quick10K
Luckwel Pharmaceuticals
10-Q 2019-06-30 Quarter: 2019-06-30
10-K 2019-03-31 Annual: 2019-03-31
10-Q 2018-12-31 Quarter: 2018-12-31
10-Q 2018-09-30 Quarter: 2018-09-30
10-Q 2018-06-30 Quarter: 2018-06-30
10-K 2018-03-31 Annual: 2018-03-31
10-Q 2017-12-31 Quarter: 2017-12-31
10-Q 2017-09-30 Quarter: 2017-09-30
10-Q 2017-06-30 Quarter: 2017-06-30
10-K 2017-03-31 Annual: 2017-03-31
10-Q 2016-12-31 Quarter: 2016-12-31
10-Q 2016-09-30 Quarter: 2016-09-30
10-Q 2016-06-30 Quarter: 2016-06-30
10-K 2016-02-29 Annual: 2016-02-29
10-Q 2015-11-30 Quarter: 2015-11-30
10-Q 2015-08-31 Quarter: 2015-08-31
10-Q 2015-05-31 Quarter: 2015-05-31
10-K 2015-02-28 Annual: 2015-02-28
10-Q 2014-11-30 Quarter: 2014-11-30
10-Q 2014-08-31 Quarter: 2014-08-31
10-Q 2014-05-31 Quarter: 2014-05-31
8-K 2019-06-12 Accountant, Exhibits
8-K 2019-03-14 Enter Agreement, Exhibits
8-K 2018-10-11 Enter Agreement, Exhibits
8-K 2018-06-20 Enter Agreement, Exhibits
8-K 2018-05-07
8-K 2018-04-13 Amend Bylaw, Exhibits
WYN Wyndham 10,152
FHLB Federal Home Loan Bank of Atlanta 493
CCUR CCUR 32
CLOW Cloudweb 2
FVRG Forevergreen Worldwide 0
EETA Eco Energy Tech Asia 0
WSCC Waterside Capital 0
NVL Novelis 0
SKVI Skinvisible 0
NSPW Northern States Power 0
LWEL 2019-06-30
Part 1 - Financial Information
Item 1 -Financial Statements
Note 1 - Organization and Description of Business
Note 2 - Summary of Significant Accounting Policies
Note 3 - Going Concern
Note 4 - Related Party Transactions
Note 5 - Capital Stock
Note 6 - Subsequent Events
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Item 4. Controls and Procedures
Part II - Other Information
Item 1. Legal Proceedings
Item 1A. Risk Factors
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Item 3. Defaults Upon Senior Securities
Item 4. Mine Safety Disclosures
Item 5. Other Information
Item 6. Exhibits
EX-31.1 ex31-1.htm
EX-32.1 ex32-1.htm

Luckwel Pharmaceuticals Earnings 2019-06-30

LWEL 10Q Quarterly Report

Balance SheetIncome StatementCash Flow

10-Q 1 form10-q.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

(Mark One)

 

[X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the quarterly period ended June 30, 2019

 

[  ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934

 

For the transition period from _________ to _________

 

Commission File Number: 333-187874

 

LUCKWEL PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

 

Nevada   46-1660653

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

 

303 Wyman Street Suite 300, Waltham, MA 02451

(Address of principal executive offices) (Zip Code)

 

(781) 728 0007

(Registrant’s telephone number, including area code)

 

 

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days [X] Yes [  ] No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). [  ] Yes [X] No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer [   ] Accelerated filer [   ]
Non-accelerated filer [X] Smaller reporting company [X]
    Emerging growth company [X]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [X] Yes [  ] No

 

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

 

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. [  ] Yes [  ] No

 

APPLICABLE ONLY TO CORPORATE ISSUERS:

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

The number of shares of common stock, par value $0.01 outstanding as of August 14, 2019 as 143,376,000.

 

 

 

   

 

 

 LUCKWEL PHARMACEUTICALS INC.

Form 10-Q

Three Months Ended June 30, 2019

 

TABLE OF CONTENTS

 

    Page
  PART I – Financial Information  
     
Item 1: Financial Statements 3
     
  Condensed Balance Sheets as of June 30, 2019 (unaudited) and March 31, 2019; 3
     
  Condensed Statements of Operations for the Three Months Ended June 30, 2019 and 2018 (unaudited); 4
     
  Condensed Statement of Changes in Stockholders’ Deficit for the Three Months Ended June 30, 2019 and 2018 (unaudited); 5
     
  Condensed Statement of Cash Flows for the Three Months Ended June 30, 2019 and 2018 (unaudited); 6
     
  Notes to Condensed Financial Statements (unaudited); 7
     
Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations 11
     
Item 3: Quantitative and Qualitative Disclosures About Market Risk 13
     
Item 4: Controls and Procedures 13
     
  PART II – Other Information  
     
Item 1: Legal Proceedings 15
     
Item 1A: Risk Factors 15
     
Item 2: Unregistered Sales of Equity Securities and Use of Proceeds 15
     
Item 3: Defaults Upon Senior Securities 15
     
Item 4: Mine Safety Disclosures 15
     
Item 5: Other Information 15
     
Item 6: Exhibits 15
     
Signatures 16

 

 2 

 

 

PART 1 – FINANCIAL INFORMATION

 

ITEM 1 –FINANCIAL STATEMENTS

 

LUCKWEL PHARMACEUTICALS INC.

CONDENSED BALANCE SHEETS

 

   June 30, 2019   March 31, 2019 
    

(Unaudited)

      
Assets          
Current Assets          
Cash  $72,394   $25,754 
Prepaid expense and other current assets   13,133    1,516 
Total Assets  $85,527   $27,270 
           
Liabilities          
Current Liabilities:          
Accrued liabilities  $111,944   $67,843 
Due to officer   905,920    751,250 
Total Liabilities   1,017,864    819,093 
           
Stockholders’ Deficit:          
Common stock, $0.01 par value; 200,000,000 shares authorized; 143,376,000 shares issued and outstanding as of June 30, 2019 and March 31, 2019, respectively.   1,433,760    1,433,760 
Additional paid in capital   465,748    465,748 
Accumulated other comprehensive income   10    10 
Accumulated deficit   (2,831,855)   (2,691,341)
Total stockholders’ deficit   (932,337)   (791,823)
Total Liabilities and Stockholders’ Deficit  $85,527   $27,270 

 

The accompanying notes are an integral part of these condensed financial statements.

 

 3 

 

 

LUCKWEL PHARMACEUTICALS INC.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

 

  

For the Three Months Ended

June 30,

 
   2019   2018 
         
General and administrative expenses  $(140,515)  $(220,356)
Other income   1    3 
           
Net loss  $(140,514)  $(220,353)
           
Net loss per share – basic and diluted  $(0.001)  $(0.002)
           
Weighted average common shares outstanding–basic and diluted   143,376,000    98,046,330 

 

The accompanying notes are an integral part of these condensed financial statements.

 

 4 

 

 

LUCKWEL PHARMACEUTICALS INC.

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

(Unaudited)

 

Three Months Ended June 30, 2019

 

   Common Stock  

Additional

Paid-in

  

Accumulated other

Comprehensive

   Accumulated  

Total

Stockholders’

 
   Shares   Amount   Capital   Income   Deficit   Deficit 
Balance as of April 1, 2019   143,376,000   $1,433,760   $465,748   $10   $(2,691,341)  $(791,823)
Net loss   -    -    -    -    (140,514)   (140,514)
Balance as of June 30, 2019   143,376,000   $1,433,760   $465,748   $10   $(2,831,855)  $(932,337)

 

Three Months Ended June 30, 2018

 

   Common Stock  

Additional

Paid-in

  

Accumulated other

Comprehensive

   Accumulated  

Total

Stockholders’

 
   Shares   Amount   Capital   Income   Deficit   Deficit 
                         
Balance as of April 1, 2018   18,376,0000   $183,760   $1,715,748   $10   $(2,028,815)  $(129,297)
Common stock issued for services   125,000,000    1,250,000    (1,250,000)   -    -    - 
Capital distribution   -    -    -    -    (40,000)   (40,000)
Net loss   -    -    -    -    (220,353)   (220,353)
Balance as of June 30, 2018   143,376,000   $1,433,760   $465,748   $10   $(2,289,168)  $(389,650)

 

The accompanying notes are an integral part of these condensed financial statements.

 

 5 

 

 

LUCKWEL PHARMACEUTICALS INC.

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   For the Three Months Ended 
   June 30, 
   2019   2018 
         
Cash Flows from Operating Activities          
Net loss  $(140,514)  $(220,353)
Adjustment to reconcile net loss to net cash used in operating activities:          
Changes in operating assets and liabilities:          
Prepaid expense and other current assets   (11,617)   - 
Accrued liabilities   44,101    7,468 
Net cash used in operating activities   (108,030)   (212,885)
           
Cash Flows from Financing Activities          
Proceeds from officer loans   154,670    268,834 
Capital distribution   -    (40,000)
Net cash provided by financing activities   154,670    228,834 
           
Net increase in cash   46,640    15,949 
           
Cash, beginning of period   25,754    18,503 
           
Cash, End of period  $72,394   $34,452 
           
Supplemental disclosures of cash flow information:          
Cash paid for interest  $-   $- 
Cash paid for income taxes  $-   $- 

 

The accompanying notes are an integral part of these condensed financial statements.

 

 6 

 

 

LUCKWEL PHARMACEUTICALS INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

Note 1 – Organization and Description of Business

 

Luckwel Pharmaceuticals Inc. (“Luckwel” or the “Company”) plans to acquire, develop, manufacture and market pharmaceutical medication.

 

Luckycom Limited, a wholly-owned subsidiary of the Company, was incorporated in Hong Kong as Goldsans Capital (Hong Kong) Limited (“Goldsans”) on November 8, 2011. Goldsans name was changed to Wudor Capital Hong Kong Limited on May 22, 2012 and subsequently to Luckycom Limited on June 28, 2013.

 

On April 11, 2018, Luckwel filed a Certificate of Amendment to the Articles of Incorporation to change its name from Luckycom Pharmaceuticals Inc. to Luckwel and to increase the number of its authorized shares of common stock to 200,000,000 with an effective date of April 13, 2018. The Company then amended and restated its by-laws to reflect the new corporate name.

 

The Company’s corporate office is located in Waltham, Massachusetts and is incorporated in the State of Nevada.

 

As used in this Quarterly Report on Form 10-Q (“Quarterly Report”), unless otherwise indicated, all references herein to “Luckwel,” the “Company,” “we” or “us” refer to Luckwel Pharmaceuticals Inc.

 

Note 2 - Summary of Significant Accounting Policies

 

Preparation of Interim Financial Statements

 

The accompanying condensed financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America for interim financial information and the Securities and Exchange Commission instructions to Form 10-Q. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the interim period ended June 30, 2019 are not necessarily indicative of the results that can be expected for the full year. The condensed financial statements contained herein should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2019 filed with the SEC on July 2, 2019.

 

These condensed financial statements have been prepared on the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. This assumption is presently uncertain and contingent upon the Company’s ability to raise additional working capital. The financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Basis of Presentation

 

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and are presented in US dollars (“USD”).

 

Cash

 

Cash includes all cash in bank with no restrictions. The Company had $72,394 and $25,754 of cash as of June 30, 2019 and March 31, 2019, respectively.

 

 7 

 

 

LUCKWEL PHARMACEUTICALS INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

Note 2 – Summary of Significant Accounting Policies (Continued)

 

Fair Value of Financial Instruments

 

Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement, defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 utilizes quoted market prices in markets that are not active, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.

 

The Company’s financial instruments consist of cash, accrued liabilities and due to officer. The carrying amount of these financial instruments approximate fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. There were no financial instruments classified as Level 3 in the fair value hierarchy during the three months ended June 30, 2019 and June 30, 2018, respectively.

 

Income Taxes

 

During the three months ended June 30, 2019 and 2018, there was no provision for income taxes as the Company incurred losses during both periods. Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

 

Uncertain tax positions

 

The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. Interest and penalties related to uncertain tax positions are recognized and recorded as necessary in the provision for income taxes. Tax years from 2013 forward remain open to examination by the U.S. federal tax authority due to the carryover of net operating losses or tax credits. According to Hong Kong Inland Revenue Department, the statute of limitation is six years if any company chargeable with tax has not been assessed at less than the proper amount. The statute of limitation is extended to 10 years if the underpayment of taxes is due to fraud or willful evasion. There were no uncertain tax positions as of June 30, 2019 and March 31, 2019.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Basic and Diluted Net Loss Per Share

 

Basic loss per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted loss per share is calculated by dividing the Company’s net loss available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There were no potentially dilutive debt or equity outstanding as of June 30, 2019 and March 31, 2019, respectively.

 

Recent Accounting Pronouncements

 

The Company does not believe any recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the financial position, statements of operations and cash flows.

 

 8 

 

 

LUCKWEL PHARMACEUTICALS INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

Note 3 – Going Concern

 

The Company does not have any sources of revenues and needs additional cash resources to maintain its operations. At June 30, 2019, we have $72,394 in cash and a net working capital deficit of $932,337, have incurred losses since inception of $2,831,855, and have not yet received any revenue from sales of products or services. These factors raise substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern is dependent on our ability to raise additional capital or obtain necessary debt financing. We are presently dependent on our Chief Executive Officer, Mr. Kingrich Lee to either provide us funding for its daily operation and expenses, including professional fee and fees charged by regulators, although he is under no obligation to do so, or to spearhead financing efforts with third parties.

 

We currently do not have any arrangements in place to complete any financings and there is no assurance that we will be successful in completing any such financings on terms that will be acceptable.

 

Our priority, should we receive such additional funds is to pay our legal, accounting and other fees associated with our Company and our filing obligations under United States federal securities laws, as well as to pay its other accounts payable generated in the ordinary course of our business.

 

The financial statements have been prepared on a going concern basis which assumes we will be able to realize its assets and discharge our liabilities in the normal course of business for the foreseeable future. We have incurred losses and further losses are anticipated as a result of the development of business which raises substantial doubt about our ability to continue as a going concern within the next twelve months from the issuance date of the financial statements. The ability to continue as a going concern is dependent upon our generating profitable operations in the future and/or obtaining financing necessary to meet our obligations and repay our liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and/or private placement of our common stock.

 

 9 

 

 

LUCKWEL PHARMACEUTICALS INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

Note 4 – Related Party Transactions

 

The Company’s sole officer and director, and also a shareholder, Mr. Kingrich Lee, loaned an aggregate of $154,670 in cash to the Company during the three months ended June 30, 2019.

 

Accordingly, Mr. Kingrich Lee is owed an aggregate amount of $905,920 and $751,250 as of June 30, 2019 and March 31, 2019, respectively, from the Company.

 

The amounts are unsecured, non-interest bearing and are due on demand.

 

On May 3, 2018, the Company entered into an Intellectual Property Sale and Purchase Agreement (the “Agreement”) with Luckwel Asia Limited (the “Seller”, formerly known as Essential Choice Ventures Ltd), an entity under common control of Mr. Kingrich Lee to purchase from the Seller the intellectual property rights to five drugs, comprising three generic medicines used to treat hypertension and high cholesterol and two advanced drug candidates - KL008 for treatment of hypertension and KL009 for treatment of high cholesterol in various stages of being developed and manufactured (the “Transaction”). Pursuant to the terms of the Agreement, the Company would pay the Seller on closing (i) $40,000 and (ii) issue an aggregate 125,000,000 restricted shares of its common stock, par value $0.01. The Transaction closed on May 3, 2018. The Company recorded the carrying value of the intellectual property as nil in the Seller’s record, $40,000 as capital distribution to the Seller and recorded the par value of the common stock as additional paid-in capital, which was due to the Transaction being regarded as an equity transaction because both parties were under common control.

 

On November 1, 2017, the Company entered into an employment agreement with Mr. Kingrich Lee. The agreement is for one year, renewable for successive one-year terms if not terminated, and provides an annual compensation of $180,000, and other benefits, including housing and education allowances. On November 1, 2018, the Company renewed the employment agreement with Mr. Kingrich Lee for another one-year term.

 

Note 5 – Capital Stock

 

As of June 30, 2019 and 2018, the Company had 143,376,000 shares of common stock issued and outstanding. During the three months ended June 30, 2018, the Company issued an aggregate of 125,000,000 restricted shares of its common stock to Luckwel Asia Limited. 

 

Note 6 – Subsequent Events

 

The Company has evaluated subsequent events subsequent to the balance sheet date through the date of this filing and determined that there were no such events requiring recognition or disclosure in the financial statements.

 

 10 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-Looking Statements

 

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

 

Overview

 

We are presently still a shell company and have not begun operations. As reflected in the accompanying condensed financial statements we have no sources of revenue and need additional cash resources to maintain our operations. At June 30, 2019, we have $72,394 in cash and a net working capital deficit of $932,337, have incurred losses since inception of $2,831,855, and have not yet received any revenue from sales of products or services. These factors raise substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern is dependent on our ability to raise additional capital or obtain necessary debt financing. We are presently dependent on our Chief Executive Officer, Mr. Kingrich Lee, to either provide us funding for its daily operation and expenses, including professional fee and fees charged by regulators, although he is under no obligation to do so, or to spearhead financing efforts with third parties.

 

We currently do not have any arrangements in place to complete any financings and there is no assurance that we will be successful in completing any such financings on terms that will be acceptable.

 

Our priority, should we receive such additional funds, is to pay our legal, accounting and other fees associated with our Company and our filing obligations under United States federal securities laws, as well as to pay our other accounts payable generated in the ordinary course of business.

 

Once these costs are accounted for, we will focus on the following activities:

 

1.

Establish a management team by December 2019 to work on establishing pharmaceutical operations in Boston focusing on

 

LWEL-1807(previously referred to as “KL-007”, a pipeline drug for malarial disease.

 

LWEL-1808 (previously referred to as “KL-008”), a pipeline drug for the treatment of gastrointestinal stromal tumor(GIST).

   
  LWEL-1809 (previously referred to as “KL-009”) for treating rheumatoid arthritis candidate drug.
   
2. Start intellectual property registration work by December 2019.
   
3. Launch  generic oncological and rheumatic arthritis drugs with operations in Houston & Hong Kong.

 

Any failure to raise money will have the effect of delaying the timeframes in our business plan as set forth above, and we may have to push back the dates of such activities.

 

 11 

 

 

Results of Operations

 

Three Months Ended June 30, 2019 Compared to Three Months Ended June 30, 2018 

 

Operating Revenue

 

We recorded no revenue for the three months ended June 30, 2019 and June 30, 2018, as we are a shell company without any operations to generate revenue.

 

Operating Expenses

 

We had operating expenses of $140,515 and $220,356 for the three months ended June 30, 2019 and 2018, respectively.

 

Our operating expenses for the three months ended June 30, 2019 consisted mainly of professional fees of $52,883, officer compensation of $66,889 and travel expenses of $13,600. Operating expenses decreased significantly from the comparable prior period is because we attended fewer conferences and meetings and spent less on office expenses.

 

Our operating expenses for the three months ended June 30, 2018 consisted mainly of professional fees of $64,712, officer compensation of $54,000, travel expenses of $23,268, and office expenses of $77,429.

 

We anticipate our operating expenses will increase significantly as we proceed to implement our business plan described above and become operational.

 

Net Loss

 

We incurred a net loss of $140,514 and $220,353 for the three months ended June 30, 2019 and 2018, respectively.

 

Liquidity and Capital Resources

 

As of June 30, 2019, we had $85,527 in current assets, consisting of $72,394 in cash and $13,133 in prepaid expense, and current liabilities in the amount of $1,017,864, consisting of accrued liabilities of $111,944, and $905,920 due to an officer. We had a net working capital deficit of $932,337 as of June 30, 2019.

 

The table below sets forth selected cash flow data for the periods presented:

 

   Three Months Ended 
   June 30, 
   2019   2018 
Net cash used in operating activities  $(108,030)  $(212,885)
Net cash provided by financing activities   154,670    228,834 
Net increase in cash  $46,640   $15,949 

 

 12 

 

 

Our negative operating cash flows were mainly a result of operating expenses and no revenue (See also Result of Operations).

 

Our positive financing cash flows were a result of proceeds from officer loans.

 

On November 1, 2017, the Company entered into an employment agreement with Mr. Kingrich Lee. The agreement is for one year, renewable for successive one-year terms if not terminated, and provides an annual compensation of $180,000, and other benefits, including housing and education allowances. On November 1, 2018, the Company renewed the employment agreement with Mr. Kingrich Lee for another one-year term. This agreement will materially impact our cash needs in the future, as any investment money we obtain will be used to pay Mr. Kingrich Lee’s salary and other benefits, and will have the effect of diverting funds that may be used to pursue our business plan.

 

We have $72,394 in cash as of June 30, 2019, which is insufficient to operate our business at the current level for the next 12 months from the issuance date of this report and insufficient cash to achieve our business goals. The success of our business plan beyond the next 12 months from the issuance date of this report is contingent upon us obtaining additional financing. We intend to fund operations through debt and/or equity financing arrangements, which may be insufficient to fund our capital expenditures, working capital, or other cash requirements. We do not have any formal commitments or arrangements for the sale of stock or the advancement of loans of funds at this time. There can be no assurance that such additional financing will be available to us on acceptable terms, or at all.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

Not required for smaller reporting companies.

 

Item 4. Controls and Procedures

 

Disclosure Controls and Procedures

 

We conducted an evaluation, with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as of June 30, 2019, to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is (i) recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive and Chief Financial Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our Chief Executive and Chief Financial Officer has concluded that as of June 30, 2019, our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses identified below.

 

 13 

 

 

Our principal chief executive officer and principal chief financial officer does not expect that our disclosure controls or internal controls will prevent all error and all fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute assurance that the objectives of the system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

Remediation Plan to Address the Material Weaknesses in Internal Control over Financial Reporting

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934). Management has assessed the effectiveness of our internal control over financial reporting as of June 30, 2019 based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. As a result of this assessment, management concluded that, as of June 30, 2019, our internal controls over financial reporting were not effective. The material weaknesses identified related to (i) a lack of accounting staff and resources with appropriate knowledge of U.S. GAAP and SEC reporting and compliance requirements; (ii) a lack of sufficient documented financial closing policies and procedures; and (iii) a lack of independent directors and an audit committee.

 

We plan to take steps to enhance and improve the design of our internal control over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we hope to implement the following changes during our fiscal year ending March 31, 2020: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; (ii) adopt sufficient written policies and procedures for accounting and financial reporting, and (iii) strengthen our financial team by employing more qualified accountant(s) conversant with US GAAP to enhance the quality of our financial reporting function. The remediation efforts set out in (i), (ii) and (iii) are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

 

Changes in Internal Control over Financial Reporting

 

During the quarter ended June 30, 2019, there have been no changes in our internal control over financial reporting that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 14 

 

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings

 

We are not a party to any pending legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

 

Item 1A. Risk Factors

 

Not required for smaller reporting companies.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3. Defaults upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

Item 6. Exhibits

 

Exhibit Number   Description of Exhibit
     
31.1*   Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1**   Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101.INS*   XBRL Instance Document
     
101.SCH*   XBRL Taxonomy Extension Schema Document
     
101.CAL*   XBRL Taxonomy Calculation Linkbase Document
     
101.DEF*   XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB*   XBRL Taxonomy Label Linkbase Document
     
101.PRE*   XBRL Taxonomy Presentation Linkbase Document

 

* Filed herewith

**Furnished herewith

 

 15 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Luckwel Pharmaceuticals Inc.  
     
Date: August 14, 2019  
     
By: /s/ Kingrich Lee  
  Kingrich Lee  
Title: Chief Executive Officer and Chief  
 

Financial Officer (Principal Executive

Officer and Principal Accounting and Financial Officer)

 

 

 16